# US 2026/0218156 A1 · Uropathogenic escherichia coli recombinant protein composition ls, construction, expression, and purification method therefor, and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0218156 A1
- Document ID: US20260218156A1
- Status: Published application
- Kind: A1
- Application number: 19/140,351
- Filed: 2024-01-24
- Published: 2026-07-30
- Earliest claimed: 2023-07-19
- Assignees: Zhejiang Chinese Medical University
- Applicants: Zhejiang Chinese Medical University
- Inventors: Aisong ZHU; Hongxia NIU; Quanjie HU; Zhuoxuan LV; Shuai ZHOU
- Web page: https://patentgrep.com/patent/US20260218156A1

## CPC

- C12N 9/90: Isomerases (5.)
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 39/0258: {Escherichia}
- A61K 39/12: Viral antigens
- A61P 37/04: Immunostimulants
- B01D 15/3828: {Ligand exchange chromatography, e.g. complexation, chelation or metal interaction chromatography}
- C12N 15/70: Vectors or expression systems specially adapted for E. coli
- C12Y 502/01008: Peptidylprolyl isomerase (5.2.1.8), i.e. cyclophilin
- C12Y 503/01028: D-Sedoheptulose 7-phosphate isomerase (5.3.1.28)
- A61K 2039/523: {expressing foreign proteins}
- A61K 2039/55505: {Inorganic adjuvants}
- A61K 2039/575: {humoral response}
- A61K 2039/70: {Multivalent vaccine}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- B01D: SEPARATION (separating solids from solids by wet methods B03B, B03D; by pneumatic jigs or tables B03B; by other dry methods B07; magnetic or electrostatic separation of solid materials from solid materials or fluids, separation by high-voltage electric fields B03C; centrifuges, vortex apparatus B04; presses per se for squeezing-out liquid from liquid-containing material B30B9/02; treatment of water C02F, e.g. softening by ion-exchange C02F1/42; {arrangements of air intake cleaners in gas turbine plants F02C7/05} ; arrangements or mounting of filters in air-conditioning, air-humidification or ventilation F24F13/28)
- C12Y: ENZYMES
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

A uropathogenic E. coli recombinant protein composition LS, a construction, expression, and purification method therefor, and a use thereof are belong to the technical field of genetic engineering. Performing PCR amplification on LpcA and SurA genes, and respectively inserting the LpcA and SurA genes into multiple cloning sites of a cloning vector to construct recombinant vectors; followed by transforming the recombinant vectors into E. coli for protein expression; and finally performing purification to obtain the composition LS of recombinant proteins LpcA and SurA applicable in urinary tract infection vaccines. The advantages are: the protein vaccine can induce stronger cellular and humoral immune responses in animals; and animal challenge experiments demonstrate its protective efficacy in reducing bacterial loads in the bladder and kidneys.

## Claims

### Claim 1

A uropathogenic E. coli recombinant protein composition LS, consisting of a recombinant protein LpcA and a recombinant protein SurA, wherein the recombinant protein LpcA has an amino acid sequence shown in SEQ ID NO: 2, and the recombinant protein SurA has an amino acid sequence shown in SEQ ID NO: 4.

### Claim 2 (depends on 1)

The uropathogenic E. coli recombinant protein composition LS of claim 1, wherein a mass ratio of the recombinant protein LpcA to the recombinant protein SurA is 1:1.

### Claim 3

(canceled)

### Claim 4 (depends on 1)

A use of the uropathogenic E. coli recombinant protein composition LS of claim 1 for preparing a vaccine for preventing uropathogenic E. coli-induced urinary tract infections.

### Claim 5 (depends on 1)

A preparation method for the uropathogenic E. coli recombinant protein composition LS of claim 1, comprising the following steps:
1) performing PCR amplification on LpcA and SurA genes, and respectively inserting the LpcA and SurA genes into multiple cloning sites of a cloning vector pET30a(+) to construct recombinant vectors pET30a(+)-LpcA and pET30a(+)-SurA;
2) transforming the recombinant vectors into E. coli to obtain a strain expressing the fusion recombinant proteins expressing the fusion recombinant proteins LpcA and SurA, and utilizing the strain to express the recombinant proteins LpcA and SurA; and
3) purifying the recombinant proteins LpcA and SurA.

### Claim 6 (depends on 5)

The method of claim 5, wherein the step 1) specifically comprises:
(1) based on gene sequences of LpcA GeneID: 949134, 579 bp and SurA GeneID: 944812, 1287 bp from E. coli str. K-12 in GenBank, along with restriction sites of the cloning vector, designing upstream and downstream primers containing endonucleases: SurA F and SurA R as well as LpcA F and LpcA R respectively, a nucleotide sequence of the SurA F is as shown in SEQ ID NO: 5, a nucleotide sequence of the SurA R is as shown in SEQ ID NO: 6, a nucleotide sequence of the LpcA F is as shown in SEQ ID NO: 7, and a nucleotide sequence of the LpcA R is as shown in SEQ ID NO: 8;
(2) extracting DNA from a uropathogenic E. coli strain UTI89 as a template, performing the PCR amplification on the gene sequences of LpcA and SurA using the primers obtained in the step (1), and purifying LpcA and SurA PCR amplification products by gel extraction for later use;
(3) extracting a pET30a(+) plasmid: amplifying an E. coli strain containing the pET30a(+) plasmid to 5 mL, and extracting the pET30a(+) plasmid using a plasmid extraction kit; and
(4) digesting the LpcA and SurA PCR amplification products obtained from the step (2) and the pET30a(+) plasmid extracted from the step (3) with EcoRI and HindIII restriction endonucleases; purifying the digested LpcA and SurA PCR amplification products and the digested pET30a(+) plasmid through PCR product purification and gel extraction; ligating the purified LpcA gene and the pET30a(+) plasmid as well as the purified SurA gene and the pET30a(+) plasmid using a T4 DNA ligase; and transforming ligation products into an E. coli DH5a, picking positive clones through an antibiotic plate screening, extracting plasmids, and performing sequencing identification to obtain the recombinant vectors pET30a(+)-LpcA and pET30a(+)-SurA.

### Claim 7 (depends on 5)

The method of claim 5, wherein the step 2) specifically comprises:
(a) transforming the successfully constructed plasmid vectors pET30a(+)-LpcA and pET30a(+)-SurA respectively into an E. coli expression strain BL21 (DE3) to obtain a recombinant protein-preserving strain;
(b) subjecting the recombinant protein-preserving strain obtained in the step (a) to activation, shaking amplification culture, induction-shaking culture, and centrifugation in sequence to obtain a bacterial cell of the recombinant protein-preserving strain; and
(c) resuspending the bacterial cell obtained in the step (b) in a PB buffer, performing sonication in an ice bath and centrifugation, collecting a supernatant and a pellet separately, and analyzing the supernatant and the pellet separately by polyacrylamide gel electrophoresis to assess protein expression profiles.

### Claim 8 (depends on 5)

The method of claim 5, wherein the step 3) specifically comprises:
(A) performing large-scale amplification on the strain expressing the fusion recombinant proteins LpcA and SurA, resuspending a harvested bacterial cell in a PB buffer, performing sonication in an ice bath and centrifugation, collecting a supernatant containing the recombinant proteins LpcA and SurA, and performing sterilization by filtration for later use; and
(B) taking purified LpcA and SurA from the supernatant obtained in the step (A) for affinity chromatography and elution to obtain the recombinant proteins LpcA and SurA.

### Claim 9 (depends on 8)

The method of claim 8, wherein the affinity chromatography and the elution in the step (B) specifically comprise: first, rinsing an empty chromatography column with sterile water to ensure a smooth flow, adding 1 mL of a nickel-charged metal affinity chromatography medium (Ni-NTA) along an inner wall of the column, and after equilibrating the medium with 10 mL of imidazole binding buffer, loading the supernatant containing the recombinant proteins LpcA and SurA onto the medium for binding; then, washing the column with 10 mL of an imidazole binding buffer and 10 mL of an imidazole wash buffer in sequence, and performing a gradient elution using 50 mM, 100 mM, 200 mM, and 300 mM imidazole elution buffers; and performing elution using a 200-300 mM imidazole elution buffer to obtain the recombinant protein LpcA and performing elution using the 200-300 mM imidazole elution buffer to obtain the recombinant protein SurA, and after protein quantification, storing the recombinant proteins LpcA and SurA for later use.

### Claim 10 (depends on 2)

A use of the uropathogenic E. coli recombinant protein composition LS of claim 2 for preparing a vaccine for preventing uropathogenic E. coli-induced urinary tract infections.
